Related Experiment Video

Updated: Jun 30, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Arrhythmogenic substrates in myocardial infarct

Tetsuro Takamatsu1

  • 1Department of Pathology and Cell Regulation, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto 602-8566, Japan. ttakam@koto.kpum.ac.jp

Pathology International
|September 20, 2008
PubMed

Insights

Intracellular calcium (Ca2+) dynamics and connexin43 (Cx43) gap junctions are key substrates in infarcted hearts that cause life-threatening ventricular tachyarrhythmias. Understanding these mechanisms offers new therapeutic strategies for cardiovascular diseases.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Molecular Biology

Background:

  • Life-threatening ventricular tachyarrhythmias are common in ischemic heart disease, particularly after myocardial infarction.
  • While electrophysiological mechanisms are known, arrhythmogenic substrates within infarcts remain unclear.

Purpose of the Study:

  • To review the roles of intracellular calcium (Ca2+) dynamics and connexin43 (Cx43) gap junctions in arrhythmogenesis in infarcted hearts.
  • To explore how Ca2+ waves and Cx43 gap junction remodeling contribute to arrhythmias.

Main Methods:

  • Review of recent literature on Ca2+ dynamics and Cx43 gap junctions in cardiac arrhythmias.
  • Focus on advancements in Ca2+-sensitive fluorescent dyes and microscopy imaging techniques.

Main Results:

  • Ca2+ waves, arising from overloaded intracellular Ca2+ in injured myocardium, are crucial in triggered arrhythmias.
  • Cx43 gap junction remodeling alters electrical coupling, contributing to re-entrant tachyarrhythmias.

Conclusions:

  • Ca2+ dysregulation and altered gap junction communication are significant substrates for ventricular tachyarrhythmias in infarcted hearts.
  • Clarifying these substrates provides insights into arrhythmia origins and potential therapeutic targets for cardiovascular diseases.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...